BGB-R046
- Generic Name
- BGB-R046
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 74
- Registration Number
- NCT06487858
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath